Bezafibrate for the treatment of primary sclerosing cholangitis

作者：Mizuno Suguru; Hirano Kenji^*; Tada Minoru; Yamamoto Keisuke; Yashima Yoko; Yagioka Hiroshi; Kawakubo Kazumichi; Ito Yukiko; Kogure Hirofumi; Sasaki Takashi; Arizumi Toshihiko; Togawa Osamu; Matsubara Saburo; Nakai Yousuke; Sasahira Naoki; Tsujino Takeshi; Isayama Hiroyuki; Kawabe Takao; Omata Masao; Koike Kazuhiko

来源：Journal of Gastroenterology, 2010, 45(7): 758-762.

DOI：10.1007/s00535-010-0204-x

• Primary sclerosing cholangitis
• Drug therapy
• Bezafibrate

It is known that bezafibrate decreases serum alkaline phosphatase (ALP) in patients with hyperlipidemia, and the efficacy of this drug for the treatment of primary biliary cirrhosis has been confirmed. However, there has been little evidence of its efficacy for the treatment of primary sclerosing cholangitis (PSC).
Bezafibrate (400 mg/day) was orally administered to 7 consecutive patients with PSC, and we analyzed their clinical features and the drug efficacy in terms of the effect on hepatobiliary enzymes, including ALP, gamma-glutamyl transpeptidase (gamma-GTP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) after 6 months. The latest hepatobiliary enzyme levels were also evaluated.
In 3 patients (effective group), the levels of all hepatobiliary enzymes had decreased after 6 months. Mean ALP had decreased to approximately 40% of the baseline in this group. The efficacy of bezafibrate was observed for a long period (range, 8-27 months) in these 3 patients. There seemed to be no definite association between the efficacy of bezafibrate and the clinical features in the short term.
This study showed that bezafibrate could lower the levels of hepatobiliary enzymes in about half of a cohort of patients with PSC.

• 出版日期2010-7